Tennessee Center for AIDS Research (TN-CFAR) Implementation Science Consultation Hub

田纳西州艾滋病研究中心 (TN-CFAR) 实施科学咨询中心

• 批准号: 10820025
• 负责人: SIMON Alexander MALLAL
• 金额: $ 57.79万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-04-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10820025
• 关键词: Acquired Immunodeficiency Syndrome; Address; Area; Caring; Centers for Disease Control and Prevention (U.S.); Clinic; Clinical; Collaborations; Communication; Communities; Consultations; Continuity of Patient Care; Country; County; Data Analyses; Development; Diagnosis; Education; Educational process of instructing; Eligibility Determination; Epidemic; Epidemiology; Equity; Evidence based intervention; Evidence based practice; Fellowship; Funding; Future; Goals; Grant; HIV; HIV diagnosis; Health Services; Knowledge; Lead; Learning; Manuscripts; Measures; Mentors; Mentorship; Methods; Newly Diagnosed; Organizational Culture; Outcome; Patients; Persons; Phase; Population; Populations at Risk; Positioning Attribute; Prevention; Protocols documentation; Provider; Public Health; Research; Research Infrastructure; Research Methodology; Research Personnel; Research Priority; Research Project Grants; Research Training; Self Efficacy; Series; Services; Site; System; Tennessee; Training; Translational Research; United States; United States National Institutes of Health; Universities; Viral; Virus Diseases; Work; antiretroviral therapy; care delivery; community engagement; deprivation; design; epidemic preparedness; experience; health equity; implementation facilitation; implementation fidelity; implementation research; implementation science; implementation strategy; improved; interest; multidisciplinary; online resource; pre-exposure prophylaxis; programs; racism; science education; skills; social health determinants; social stigma; socioeconomics; success; tool; uptake; workforce needs

Project Summary Human Immunodeficiency Virus (HIV) infection remains a significant public health problem in the United States (US). Despite the availability of safe and effective HIV treatment (antiretroviral therapy, ART) and prevention (pre-exposure prophylaxis, PrEP), there remains a significant proportion of people living with diagnosed HIV who have not achieved viral suppression and a significant proportion of people at risk for HIV acquisition who have not accessed PrEP. The Centers for Disease Control and Prevention estimates that there were 30, 635 people newly diagnosed with HIV in the US in 2020, with 51% located in the South. In 2019, only 56.8% had achieved viral suppression. Similarly, among the estimated 1.2 million people in the US eligible for PrEP only about 25% have accessed it. The field of implementation science provides researchers with the critical tools to address this evidence-practice gap. The development of tailored strategies designed facilitate implementation of evidence based practices can address issues with provider knowledge and self-efficacy, facilitate team communication, improve organizational culture, and create streamlined clinical systems that simplify care delivery. However, many HIV health services researchers do not have formal implementation science training or mentorship in this area. For these reasons, the United States EHE Plan and the National Institutes of Health (NIH) have prioritized the training of a multi-disciplinary workforce needed to conduct high-priority HIV research. Therefore, the overarching goal of this proposal is to continue the work of our Tennessee Center for AIDS Research Implementation Science Hub. We plan to continue supporting IS work through the provision of technical assistance, mentorship, education, and consultative services to NIH EHE implementation science awardees. The Tennessee-CFAR is uniquely positioned to serve as an Ending the HIV Epidemic IS Hub for several important reasons. First, the Tennessee Center for AIDS Research (TN-CFAR) is located in the US South, a region of the country disproportionately impacted by a high HIV burden and low numbers of PrEP users, and our team has experience addressing the prevalent social determinants of health that plague the region including racism, stigma, and socioeconomic deprivation. Second, the proposed TN- CFAR IS Hub team brings complementary expertise in implementation science, mixed methods research, epidemiology, clinical HIV care and treatment, health equity, and community engagement needed for success in carrying out HIV implementation science studies. Third, the team has long-standing collaborations with colleagues in Memphis/Shelby County, Tennessee, a Phase I EHE Priority jurisdiction that would facilitate participation in multi-site HIV implementation science hub studies. We expect that TN-CFAR Implementation Science Hub activities will help EHE awardees and their communities in reaching EHE goals through leveraging our unique academic, public health, and community-based partnerships.

项目摘要 人类免疫缺陷病毒（HIV）感染仍然是美国的一个重大公共卫生问题 （US）.尽管有安全有效的艾滋病毒治疗（抗逆转录病毒疗法）和预防措施， （暴露前预防，PrEP），仍然有很大比例的艾滋病毒感染者 没有达到病毒抑制的人和很大一部分有感染艾滋病毒风险的人， 疾病控制和预防中心估计， 2020年，美国新诊断出的艾滋病毒感染者中，51%位于南方。2019年，只有56.8%的人有 实现了病毒抑制。同样，在美国估计有120万人只适合PrEP 大约25%的人已经访问了它。实施科学领域为研究人员提供了关键工具， 解决这一证据-实践差距。制定有针对性的战略，以促进执行 基于证据的实践可以解决提供者知识和自我效能的问题， 沟通，改善组织文化，并创建简化护理的精简临床系统 交付.然而，许多艾滋病毒卫生服务研究人员没有正式的实施科学培训 或导师在这方面。由于这些原因，美国EHE计划和美国国立卫生研究院 (NIH)优先培训开展高度优先的艾滋病毒/艾滋病防治工作所需的多学科工作队伍， research.因此，这项建议的首要目标是继续我们田纳西州的工作， 艾滋病研究执行科学中心。我们计划继续支持信息系统工作， 为NIH EHE提供技术援助、指导、教育和咨询服务 执行科学奖获得者。田纳西州的CFAR是唯一的定位，作为一个结束艾滋病毒 流行病是枢纽有几个重要的原因。田纳西艾滋病研究中心（TN-CFAR） 位于美国南部，该国的一个地区不成比例地受到艾滋病毒高负担和低负担的影响。 PrEP用户的数量，我们的团队有经验解决健康的普遍社会决定因素 包括种族主义、耻辱和社会经济剥夺。其次，拟议的TN- CFAR IS Hub团队带来了实施科学，混合方法研究， 流行病学、临床艾滋病护理和治疗、卫生公平和成功所需的社区参与 开展艾滋病毒实施科学研究。第三，团队与 同事们在孟菲斯/谢尔比县，田纳西州，第一阶段EHE优先管辖区，将促进 参与多地点艾滋病毒实施科学中心研究。我们希望TN-CFAR实施 科学中心活动将帮助EHE获奖者及其社区通过以下方式实现EHE目标： 利用我们独特的学术，公共卫生和社区为基础的合作伙伴关系。

项目成果

The organizational trauma resilience assessment: Methods and psychometric properties.

• DOI: 10.1037/tra0001184
• 发表时间: 2023-09
• 期刊: PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
• 影响因子: 6.3
• 作者: Brown, Leslie Lauren;Pennings, Jacquelyn;Steckel, Sukey;Van Zyl, Michiel
• 通讯作者: Van Zyl, Michiel

The Combined Utility of Ex Vivo IFN-γ Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions.

• DOI: 10.1016/j.jaip.2017.09.004
• 发表时间: 2018-07
• 期刊: The journal of allergy and clinical immunology. In practice
• 作者: Trubiano JA;Strautins K;Redwood AJ;Pavlos R;Konvinse KC;Aung AK;Slavin MA;Thursky KA;Grayson ML;Phillips EJ
• 通讯作者: Phillips EJ

Brief Report: Circulating Markers of Immunologic Activity Reflect Adiposity in Persons With HIV on Antiretroviral Therapy.

• DOI: 10.1097/qai.0000000000001768
• 发表时间: 2018-09-01
• 期刊: Journal of acquired immune deficiency syndromes (1999)
• 作者: Koethe JR;Jenkins CA;Furch BD;Lake JE;Barnett L;Hager CC;Smith R;Hulgan T;Shepherd BE;Kalams SA
• 通讯作者: Kalams SA

Immune activation and arterial stiffness in lean adults with HIV on antiretroviral therapy.

• DOI: 10.4102/sajhivmed.v22i1.1190
• 发表时间: 2021
• 期刊: Southern African journal of HIV medicine
• 影响因子: 1.7
• 作者: Kaluba L;Goma F;Guure C;Munsaka S;Mutale W;Heimburger DC;Chikopela T;Koethe JR
• 通讯作者: Koethe JR

A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis.

基于机器学习的模型，用于自动推荐利福平耐药结核病的个体化治疗。

• DOI: 10.21203/rs.3.rs-2525765/v1
• 发表时间: 2023
• 期刊: Research square
• 作者: Verboven,Lennert;Callens,Steven;Black,John;Maartens,Gary;Dooley,KellyE;Potgieter,Samantha;Cartuyvels,Ruben;SMARTTteam;Laukens,Kris;Warren,RobinM;VanRie,Annelies
• 通讯作者: VanRie,Annelies